Showing results (31-40 of 40) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Respiration; International Review of Thoracic Diseases|November 5, 2018
Patient Satisfaction and Clinical Outcomes with Budesonide plus Formoterol Spiromax for Asthma and Chronic Obstructive Pulmonary Disease: A Real-World, Observational TrialAdrian Gillissen, Christian Gessner, Klaus Hechenbichler, et al.ERJ Open Research|October 1, 2024
Real-world use of inhaled corticosteroid/formoterol as needed in adults with mild asthma: the PRIME studyGuy Brusselle, Francesco Blasi, Christian Gessner, et al.Respiratory Medicine|March 12, 2021
Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trialsEmil Scosyrev, Richard van Zyl-Smit, Huib Kerstjens, et al.Respiratory Medicine|August 27, 2020
Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON)Christian Gessner, Oliver Kornmann, Jorge Maspero, et al.The Lancet. Respiratory Medicine|July 13, 2020
Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 studyRichard N van Zyl-Smit, Matthias Krüll, Christian Gessner, et al.Journal of Asthma and Allergy|January 30, 2023
Mometasone/Indacaterol/Glycopyrronium (MF/IND/GLY) and MF/IND at Different MF Strengths versus Fluticasone Propionate/Salmeterol Xinafoate (FLU/SAL) and FLU/SAL+ Tiotropium in Patients with AsthmaRichard N van Zyl-Smit, Kenneth R Chapman, Huib A M Kerstjens, et al.Cancer|May 8, 2023
Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: Patient-reported outcomes from phase 3 EMPOWER-Lung 3Tamta Makharadze, Ruben G W Quek, Tamar Melkadze, et al.Journal of Asthma and Allergy|March 2, 2026
Real-World Effectiveness and Safety of Single Inhaler Triple Therapy with Beclometasone/ Formoterol/ Glycopyrronium in Moderate to Severe Asthma: TriMaximize StudyChristian Gessner, Richard E K Russell, Timm Greulich, et al.American Journal of Respiratory and Critical Care Medicine|July 6, 2023
Icenticaftor, a CFTR Potentiator, in COPD: A Multicenter, Parallel-Group, Double-Blind Clinical TrialFernando J Martinez, Gerard J Criner, Christian Gessner, et al.Nature Medicine|August 25, 2022
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trialMiranda Gogishvili, Tamar Melkadze, Tamta Makharadze, et al.Pageof 4